Objective To investigate the efficacy and safety of osimertinib combined with bevacizumab in patients with EGFRT 790M mutated advanced non-small cell lung cancer(NSCLC).Methods A total of 82 patients with EGFR T790M muta-tion advanced NSCLC were selected and divided into 2 groups according to odd and even number.41 patients in the control group were treated with osimertinib and 41 patients in the study group were treated with osimertinib combined with bevacizumab.After 4 cycles of treatment,the efficacy and safety of the 2 groups were evaluated.Results After treatment,the objective remission rate(ORR),disease control rate(DCR)and T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+)levels in the study group were higher than those in the control group(P＜0.05).The levels of carcinoembryonic antigen(CEA),human cytokeratin 21-1(cy-fra21-1)and carbohydrate antigen CA125(CA125)in the study group were lower than those in the control group(P＜0.05).The adverse reactions such as anemia,rash,liver function damage,gastrointestinal reactions,proteinuria and hypertension in the 2 groups were graded as 1-2,and the difference was not statistically significant(P＞0.05).Conclusion Osimertinib combined with bevacizumab as first-line treatment for advanced NSCLC with EGFR T790M mutation can improve the immune function of pa-tients,reduce the level of tumor markers,with high clinical efficacy and good safety.
关键词
奥希替尼/贝伐珠单抗/EGFR/T790M突变/非小细胞肺癌
Key words
Osimertinib/Bevacizumab/EGFR T790M mutation/Non-small cell lung cancer
维普
万方数据